BioGeometry Closes Over $100 Million in Series A Round

AI-native biopharma company BioGeometry has closed an A+ round, bringing its total Series A financing to over $100 million, led by China Life Capital with participation from existing and new investors. The funds will go toward iterating its GeoFlow and GeoCell microworld models, expanding its high-throughput automated lab, and commercializing its in-house drug pipelines. The round shows capital backing the AI-plus-biopharma model, where model iteration and lab automation support drug discovery.

• 36氪 AI2026-10-28 02:26